Curis has halted patient enrollment for a Phase I trial of CUDC-427, its drug candidate to treat advanced solid tumors, in compliance with the FDA's decision to put the trial on partial hold. The decision was made after one of the patients died from liver failure. The agency also asked Curis to submit additional data on patients who received CUDC-427.

Full Story:

Related Summaries